RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Soleno Therapeutics Stocks 2024

Soleno Therapeutics Stocks

16.49 M

Soleno Therapeutics Dividend yield

Ticker

SLNO

ISIN

US8342032005

WKN

A2JSTG

In 2024, Soleno Therapeutics had 16.49 M outstanding stocks, a 0% change from the 16.49 M stocks in the previous year.

The Soleno Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e16.49
2025e16.49
2024e16.49
202316.49
20228.4
20215.32
20204.17
20192.28
20181.4
20170.6
20160.21
20150.13
20140.09
20130.09
20120.09

Soleno Therapeutics Aktienanalyse

What does Soleno Therapeutics do?

Soleno Therapeutics Inc is a biopharmaceutical company focused on rare diseases and unmet medical needs. The company was founded in 1999 and is headquartered in Redwood City, California. Soleno Therapeutics develops and markets innovative therapies for patients who have previously had limited or no treatment options. Business model: Soleno Therapeutics specializes in developing therapies for rare diseases. The company takes an innovative approach and utilizes cutting-edge technologies to develop drugs that have the potential to improve the lives of affected patients. The company works closely with leading research institutions and experts in the industry and invests significantly in research and development of new therapies. The company employs a two-pronged approach, developing innovative drugs for unmet medical needs while also acquiring already approved drugs and optimizing them for new applications. Soleno Therapeutics then markets these drugs to physicians, hospitals, and patients worldwide. Segments: Soleno Therapeutics specializes in developing therapies for rare diseases, focusing on three main segments: 1. Hypophosphatasia: Hypophosphatasia is a rare metabolic disorder that leads to the accumulation of phosphate in the bones and tissues. This results in weak bones, pain, and a variety of other symptoms. Soleno Therapeutics has developed a novel enzyme replacement therapy product that aims to support bone formation and alleviate the symptoms of the disease. 2. Prader-Willi Syndrome: Prader-Willi Syndrome is a rare genetic disorder characterized by obesity, mental retardation, and hormonal imbalances. Soleno Therapeutics has developed a product that suppresses hunger, helping patients develop a normal diet and achieve a healthy weight. 3. Other indications: Soleno Therapeutics is also working on developing therapies for other rare diseases and unmet medical needs, including conditions such as hemophilia, narcolepsy, and Parkinson's. Products: Soleno Therapeutics currently offers the following products: 1. Treakisym: Treakisym is a novel enzyme replacement therapy product aimed at supporting bone formation in patients with hypophosphatasia. The medication has already been approved in Japan. 2. Solinum: Solinum is a product that suppresses hunger in patients with Prader-Willi Syndrome. The medication is currently in Phase III of clinical trials and is expected to be approved in the coming years. 3. Other products: Soleno Therapeutics also has a range of other products in the pipeline, focusing on the development of therapies for rare diseases. Conclusion: Soleno Therapeutics is an innovative biopharmaceutical company specializing in the development of therapies for rare diseases and unmet medical needs. The company invests significantly in research and development of new medications and works closely with industry experts. Soleno Therapeutics has already launched an enzyme replacement therapy product for hypophosphatasia and is currently working on the approval of a hunger suppressant product for Prader-Willi Syndrome. The company also has a range of other medications in the pipeline, aiming to improve the lives of patients with rare diseases. Soleno Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Soleno Therapeutics's Shares Outstanding

Soleno Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Soleno Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Soleno Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Soleno Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Soleno Therapeutics Stock

How many stocks are there of Soleno Therapeutics?

The current number of stocks of Soleno Therapeutics is 16.49 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Soleno Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Soleno Therapeutics evolved in recent years?

The number of shares of Soleno Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Soleno Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Soleno Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Soleno Therapeutics pay?

Over the past 12 months, Soleno Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Soleno Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Soleno Therapeutics?

The current dividend yield of Soleno Therapeutics is .

When does Soleno Therapeutics pay dividends?

Soleno Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Soleno Therapeutics?

Soleno Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Soleno Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Soleno Therapeutics located?

Soleno Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Soleno Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Soleno Therapeutics from 6/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/2/2024.

When did Soleno Therapeutics pay the last dividend?

The last dividend was paid out on 6/2/2024.

What was the dividend of Soleno Therapeutics in the year 2023?

In the year 2023, Soleno Therapeutics distributed 0 USD as dividends.

In which currency does Soleno Therapeutics pay out the dividend?

The dividends of Soleno Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Soleno Therapeutics

Our stock analysis for Soleno Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Soleno Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.